Intuniv

How Hard Is It to Find Intuniv in Stock?

Intuniv (guanfacine ER) is generally available in the U.S. and is not listed on the FDA's Drug Shortage database as of 2026. Because it is not a controlled substance, it is not subject to the DEA production quotas that have created formal national shortages of stimulant ADHD medications like Adderall. This gives Intuniv a structural supply advantage over Schedule II stimulants.

However, localized pharmacy stockouts do occur. The ongoing stimulant shortage has significantly increased demand for non-stimulant ADHD alternatives including Intuniv. Generic market fragmentation — multiple manufacturers, each pharmacy stocking only one — creates situations where some strengths (particularly 3 mg and 4 mg) may be harder to find at specific locations. Rural areas and small independent pharmacies may face more variability than urban pharmacy networks.

If your local pharmacy is out of stock, start your search early and expand to independent pharmacies, grocery store pharmacies, or mail-order options. medfinder contacts pharmacies near you to find which ones can fill your Intuniv prescription — saving you hours of calls and hold time.

Who Can Prescribe Intuniv?

Because Intuniv (guanfacine ER) is not a controlled substance, any licensed prescriber with authority to write prescriptions in your state can prescribe it. There are no DEA registration requirements or special authorizations needed — a major advantage over Schedule II stimulant ADHD medications.

• Pediatricians — the most common prescribers for children and adolescents
• Child and adolescent psychiatrists — for complex ADHD with comorbidities
• Family medicine physicians — for patients of all ages
• Neurologists — for patients with tic disorders or Tourette syndrome
• Adult psychiatrists — for off-label use in adults with ADHD
• Nurse practitioners (NPs) and physician assistants (PAs) — with full prescribing authority in most states

Telehealth prescribing is fully available for Intuniv. Since it is not a controlled substance, there are no DEA restrictions on prescribing via video visit. ADHD-focused telehealth platforms and general telehealth services can prescribe Intuniv without requiring an in-person appointment — a significant advantage over stimulant ADHD medications.

Is Intuniv a Controlled Substance?

No. Intuniv (guanfacine ER) is not a controlled substance. It has no DEA schedule and is not subject to the production quotas, prescribing restrictions, or dispensing limitations that apply to Schedule II medications like Adderall, Ritalin, or Vyvanse.

This non-controlled status has significant practical advantages: Intuniv can be prescribed via telehealth without in-person DEA registration requirements, refills can be called in by phone in most states, 90-day supply prescriptions can be written without restriction, and mail-order dispensing is fully available. There is no abuse potential or dependence risk associated with guanfacine ER.

Note: Although Intuniv is not a controlled substance and doesn't have abuse potential, it should never be stopped abruptly. Sudden discontinuation can cause rebound hypertension. Always taper under medical supervision.

Common Side Effects of Intuniv

The most commonly reported side effects include:

• Somnolence (sleepiness) — most common, typically improves by weeks 8-9
• Fatigue and tiredness
• Decreased blood pressure (hypotension)
• Dizziness, especially when standing
• Headache
• Abdominal pain or nausea
• Dry mouth
• Decreased appetite (less common than with stimulants)
• Irritability, especially during dose changes

Serious side effects requiring immediate medical attention:

• Severe hypotension (extreme dizziness, difficulty breathing, fainting)
• Syncope (fainting) — occurs in approximately 1% of pediatric patients
• Bradycardia (slow heart rate) — lightheadedness, confusion, irregular heartbeat
• Rebound hypertension from abrupt discontinuation — never stop Intuniv suddenly

Final Thoughts on Intuniv

Intuniv (guanfacine ER) is one of the most supply-stable ADHD medications available in 2026. Its non-controlled status exempts it from DEA quota restrictions that have constrained stimulant supply for over three years, making it a valuable treatment option both as a standalone therapy and as an adjunct to stimulants. For families navigating the ongoing ADHD medication shortage, Intuniv represents a clinically effective alternative with a more predictable supply chain.

Generic guanfacine ER is widely available and dramatically less expensive than brand Intuniv — as low as $11-15 per month with discount coupons. Insurance coverage is broad, with generic guanfacine ER often placed on Tier 1 or Tier 2 formulary positions. Patients who encounter local pharmacy stockouts have multiple options: mail-order pharmacy, independent pharmacies, and pharmacy comparison tools.

If you're having trouble finding Intuniv at your pharmacy, medfinder calls pharmacies near you to identify which ones have your prescription in stock. Enter your medication, dosage, and location — results are texted directly to you so you can find your medication without the frustration of calling pharmacies one by one.